Skip To Main Content
Dean Fennell on Muck Rack

Dean Fennell

As seen in: Nature, BMJ Open, Thorax, The New England Journal of Medicine, The Lancet, Healio, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dean

Contact Dean, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumour extrinsic neutrophil regulation in mesothelioma correlates with responsiveness to AXL and PD1 inhibition in MIST3, a phase IIA clinical trial

|
By Dean Fennell, Joanna Dzialo, Min Zhang
| medRxiv
D.A.F. reports grants from Aldeyra, Astex Therapeutics, Bayer, BMS and Boehringer Ingelheim, Owkin; non-financial support from BerGenBio, Clovis, Eli Lilly, MSD, Roche, and Tesaro GSK; personal fees from Aldeyra, Cambridge Clinical Laboratories, Ikena, Opna Bio, Owkin, RS Oncology, Roche, MSD, during the conduct of the study.
Open in Who Shared Issue with article?

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer

|
By Victoria Gibson, Joanna Dzialo, Terri Messier, Aleksandra Bzura, Charlotte Poile, Jens C. Hahne, Aida Habibovic, Stephanie Stead, Kevin G Blyth, Peter Szlosarek, Simon Lord, Fiona Thistlethwaite, Min Zhang, Apostolos Nakas, Kudzayi Kutywayo, Kelly J Butnor, Maurice Dungey, Julio Herrero Colomina, Burak Yasin Aktas, Burak Nedim Aktaş, Sean Dulloo, James B. Spicer, Dean Fennell, Brian Cunniff, Jan Rogel, Alexis Saaman, Peter Wells-Jordan, Nicholas. H. Heintz, George N. Naumov
| Nature Verified
Abstract Cancer cells counteract oxidative stress through upregulation of antioxidant networks. Peroxiredoxin 3 (PRX3), a mitochondrial antioxidant enzyme, regulates reactive oxygen species homeostasis and promotes tumor cell survival. The natural compound thiostrepton (TS) covalently inhibits PRX3, disrupting redox balance and selectively induces tumor cell death. Mesothelioma, an aggressive malignancy, has limited therapeutic options, particularly in relapsed or refractory settings.
Open in Who Shared Issue with article?

BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities - Oncogene

|
By Dean Fennell
| Nature Verified
Abstract Mesothelioma is an aggressive cancer that is often characterized by loss of the BRCA1-associated protein 1 (BAP1) tumor suppressor gene. This alteration typically occurs as an early clonal event in mesothelioma development, making it a promising candidate for both diagnostic and therapeutic applications.
Open in Who Shared Issue with article?
See all 24 articles